Abbott's oncology expansion bolsters diagnostics, but profit drag tempers enthusiasm

What happened

Abbott's diagnostics segment has widened its base with the Exact Sciences acquisition, adding approximately $1 billion in cancer diagnostics revenue since the March 2026 close. Resilient core laboratory testing is offsetting a decline in respiratory molecular diagnostics, supporting overall diagnostics sales. However, the Exact deal remains EPS-dilutive through 2027, with higher amortization and interest costs compressing earnings. Medical devices continue to perform well, growing 8.0% ex-FX in the first half of 2026, led by electrophysiology and diabetes care. The overall picture shows diversification benefits, but the 34.5x P/E ratio prices in optimism and leaves little room for setbacks in nutrition or Libre remediation.

Implication

Abbott's move into cancer diagnostics through Exact Sciences offers a new long-term growth avenue, yet the acquisition's near-term earnings hit from interest and amortization clouds the picture. The $20 billion debt-funded deal has raised net interest expense to $367 million in 1H26, pressuring returns. While core lab testing resilience helps smooth respiratory weakness, diagnostics growth quality remains mixed. Medical devices momentum provides a buffer, but the stock's 34.5x P/E already reflects recovery hopes, leaving limited margin for error. Investors should monitor cost synergy realization and diabetes quality remediation before committing new capital, as the current setup rewards patience over aggressiveness.

Thesis delta

No material shift. The oncology expansion was fully anticipated in the Exact Sciences acquisition and recent filings. Early revenue traction is encouraging, but the dilutive impact on earnings persists, keeping the investment thesis unchanged at WAIT.